Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharma investors set plans for expedited ROI by developing products, not companies

This article was originally published in Scrip

Executive Summary

If the biotechnology industry initially embraced a credo of "The Little Engine that Could" – the story of a little railroad engine with 'can-do' attitude - a more relevant description of the last 10 years may be "Little Big Pharma," according to a recent meeting of a group of investors and executives.

You may also be interested in...

Biotech looks set for a fair 2012

Biotech companies and their backers are looking at 2012 with guarded optimism. Delegates and panellists at the recent BIO Investor Forum in San Francisco believe that the recent restructuring of companies is restoring investor confidence in the sector, with an increase interest in taking discovery platform businesses public. Moreover, participants at the meeting were predicting that biotech companies have nothing to fear from the FDA or the US presidential elections.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts